The content creator has over 65,000 followers on her style page @dressing_dawn ...

In explaining the rationale behind the study, Tang and colleagues pointed out that despite the lack of level 1 evidence, MDT ...

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a ...

A retrospective analysis finds that patients with lung-only metastatic pancreatic cancer have better overall survival, are ...

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Breast cancer has a survival rate of over 95% when detected early, but this drops sharply to around 40% in cases of ...

Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...

In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...